Non-segmental Vitiligo
Conditions
Brief summary
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study
Interventions
DRUGVC005 tablets
VC005 groups repeat administration for 52 weeks
VC005 Placebo groups repeat administration for 52 weeks
Sponsors
Jiangsu vcare pharmaceutical technology co., LTD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol. * The subject is between 18 and 70 years of age (including borderline values) , regardless of gender.
Exclusion criteria
* Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period. * All hair in the vitiligo area on the face is white. * Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs. * Subjects who have previously received depigmentation treatment. * Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage change in facial vitiligo area score index (F-VASI) relative to baseline at week 24 | Week 24 |
Countries
China
Contacts
Primary Contactxiaojuan lai
Outcome results
None listed